Project description DEENESFRITPL A robotic surgery system with haptic feedback Many endovascular procedures such as peripheral vascular surgery and coronary interventions are carried out by robotics, protecting medical personnel from exposure to harmful X-rays. The EU-funded HAPGuide project has developed a novel robotic system that allows haptic feedback and traditional control of endovascular instruments. Surgeons maintain their level of perception, visualisation and action, with no need for specialised instruments or expensive catheters. The key objective of HAPGuide is to bring this innovative technology to clinical practice for safer, faster and more effective endovascular interventions worldwide, benefitting patients, physicians and hospitals. Show the project objective Hide the project objective Objective "UAB ""Inovatyvi medicina"" has developed an innovative design of endovascular robotic system HAPGuide. This SMART and SENSING technology allows to perform endovascular procedures without medical personnel being exposed to harmful X-rays. HAPGuide solves the main issues of existing robotic systems and opens up possibilities for safer, faster and more effective endovascular interventions in EU and Worldwide. In comparison to existing systems (with only visual feedback and videogame like control) the main HAPGuide advantage is the haptic feedback and traditional control of endovascular instruments using fine-tuned surgeons’ perception-action-visualization abilities. Future developments involve HAPGuide use in telemedicine and partially automated functions via machine learning. Our system is designed to use all standard endovascular instruments and avoids the need of expensive catheters dedicated for the system. The primary target market of HAPGuide is cath labs performing percutaneous coronary interventions and peripheral vascular procedures in EU and US (more than 5.6 mln. procedures annually). The estimated market potential of HAPGuide robotic system in primary worldwide market exceeds €4 billion. The secondary target market would involve neurointerventional procedures while in the long-run expansion to telerobotics will create new market opportunities. Our revenue model involves four main components: 1) durable robotic HAPGuide system; 2) single use cassette; 3) annual service of the system; 4) HAPLearn training software. A multidisciplinary team with vast experience in medical sciences, medical device development, robotics, mechanical and electronic engineering, product design, commercialisation and business development has joined forces for the implementation of HAPGuide project aiming to bring the technology to clinical practice for benefit of patients, physicians and hospitals and exploit this €4 billion niche market commercial opportunity." Fields of science medical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesbasic medicineneurologystrokeengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringroboticsnatural sciencescomputer and information sciencesartificial intelligencemachine learningnatural sciencescomputer and information sciencessoftwaresoftware applicationsvideo games Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator UAB INOVATYVI MEDICINA Net EU contribution € 50 000,00 Address Sauletekio al 15 1 10224 Vilniaus Lithuania See on map Region Lietuva Sostinės regionas Vilniaus apskritis Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
